| Name | SBI-115 |
|---|
| Description | SBI-115 is a TGR5 (GPCR19) antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibitingTGR5[1]. |
|---|---|
| Related Catalog | |
| In Vitro | SBI-115 (100 and 200 µM, 24 hours) inhibits proliferation triggered by pre-treatment of cystic cholangiocytes with Taurolithocholic acid (TLCA) in shRNA-transfected ADPKD cholangiocytes[1]. Cell Proliferation Assay[1] Cell Line: shRNA-transfected ADPKD cholangiocytes Concentration: 100 and 200 µM Incubation Time: 24 hours Result: Inhibited proliferation (by 32-48%) triggered by pre-treatment of cystic cholangiocytes with TLCA. |
| References |
| Molecular Formula | C14H13ClN2O4S |
|---|---|
| Molecular Weight | 340.78 |
| Storage condition | 2-8℃ |